在疾病进展时，骨髓瘤患者的倍体状态很少发生变化。

Ploidy status rarely changes in myeloma patients at disease progression.

作者信息

Chng W J, Winkler J M, Greipp P R, Jalal S M, Bergsagel P L, Chesi M, Trendle M C, Ahmann G J, Henderson K, Blood E, Oken M M, Hulbert A, Van Wier S A, Santana-Dávila R, Kyle R A, Gertz M A, Lacy M Q, Dispenzieri A, Fonseca R

机构信息

Mayo Clinic Scottsdale, Comprehensive Cancer Center, Division of Haematology-Oncology, Johnson Research Building, Scottsdale, AZ 85259, USA.

出版信息

Leuk Res. 2006 Mar;30(3):266-71. doi: 10.1016/j.leukres.2005.07.004. Epub 2005 Aug 18.

DOI:10.1016/j.leukres.2005.07.004

PMID:16111750

Abstract

Hyperdiploid and non-hyperdiploid multiple myeloma represents distinct biological entities characterized by different patterns of genetic changes. We sought to determine whether ploidy category (non-hyperdiploid versus hyperdiploid) remains stable over time from diagnosis to progression. Of the 43 patients studied (39 by flow cytometry DNA index and 4 by a FISH-based index), only five (12%) altered their ploidy status at progression. In three of these patients, the change may possibly be attributable to technical artifacts because of the low absolute change in DNA index. For those who retain their ploidy subtypes, the DNA index change minimally (3.75+/-4.87%). It would appear that the initiating genetic events underlying hyperdiploid and non-hyperdiploid MM that marks them out as distinct entities continue to dominate and persist during disease evolution and progression.

摘要

超二倍体和非超二倍体多发性骨髓瘤代表了具有不同遗传变化模式的独特生物学实体。我们试图确定从诊断到疾病进展期间，倍体类别（非超二倍体与超二倍体）是否随时间保持稳定。在研究的43例患者中（39例通过流式细胞术DNA指数检测，4例通过基于荧光原位杂交的指数检测），只有5例（12%）在疾病进展时改变了倍体状态。在其中3例患者中，由于DNA指数的绝对变化较小，这种变化可能归因于技术假象。对于那些保留其倍体亚型的患者，DNA指数变化极小（3.75±4.87%）。看来，将超二倍体和非超二倍体多发性骨髓瘤标记为不同实体的初始遗传事件在疾病演变和进展过程中继续占据主导并持续存在。